| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.7M | — | +2873.4% |
| Cost of Revenue | $200K | — | — |
| R&D Expense | $100.1M | — | +31.3% |
| SG&A Expense | $50.8M | — | +43.1% |
| Operating Income | -$140.4M | — | -26.0% |
| Net Income | -$127.8M | — | -32.1% |
| EPS (Basic) | -$1.23 | — | -18.3% |
| EPS (Diluted) | -$1.23 | — | -18.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $114.3M | +12.6% | +20.9% |
| Short-term Investments | $1.18B | +27.1% | -0.2% |
| Accounts Receivable | $5.7M | +860.0% | — |
| Inventory | $3.1M | +51.5% | — |
| Current Assets | $1.32B | +26.1% | +2.4% |
| Total Assets | $1.40B | +24.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$124.7M | — | -41.0% |
| Capital Expenditures | $820K | — | -33.8% |
| Investing Cash Flow | -$252.4M | — | -193.6% |
| Financing Cash Flow | $389.9M | — | +8686.9% |
| Free Cash Flow | -$125.5M | — | -40.0% |
| +2.9% |
| Current Liabilities | $71.1M | -16.4% | +24.0% |
| Total Liabilities | $120.7M | -10.1% | +12.4% |
| Stockholders' Equity | $1.28B | +29.1% | +2.1% |